secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ceribell, Inc. (CBLL)
CIK:        0001861107
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-067136
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ceribell Q4 revenue $24.8M (+34% YoY); FY 2026 guidance $111-115M
-----------------------------------------------------------------

- Full-year 2025 revenue $89.1M (+36% YoY); net loss $53.4M ($1.46/share).
- Q4 gross margin 87%; active accounts 647; cash $159.3M.
- FY 2026 revenue guidance $111-115M, representing 25-29% growth.
- FDA 510(k) clearance for continuous delirium monitoring and neonatal seizure detection.
- FDA Breakthrough Device Designation for large vessel occlusion stroke detection solution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861107/000119312526067136/0001193125-26-067136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861107/000119312526067136/cbll-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-067136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer